Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

Circulation

Volumn 95, Issue 5, 1997, Pages 1126-1131

  O'Driscoll, Gerard ^a   Green, Danny ^a,b   Taylor, Roger R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

blood flow; cholesterol; endothelium; hypercholesterolemia

Indexed keywords

ACETYLCHOLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRAIN GAUGE TRANSDUCER; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 0031032831     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.5.1126     Document Type: Article

References (10)

1. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J. Reduction in cardiovascular events during pravastatin therapy. Circulation. 1995;92:2419-2425.
3. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimar AR, MacFarlane P, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study. N Engl J Med. 1995;333:1301-1307. See comments.
4. Brown BC, Zhao XQ, Sacco DE, Albers JJ. Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
5. Brown G, Albers JJ, Fisher L, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
6. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
7. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
8. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
9. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 1992;85:1390-1397.
10. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.